Growth Hormone II

Basic and Clinical Aspects

  • Barry B. Bercu
  • Richard F. Walker
Conference proceedings
Part of the Serono Symposia USA Norwell, Massachusetts book series (SERONOSYMP)

Table of contents

  1. Front Matter
    Pages i-xx
  2. Somatostatin/GRF Regulation

    1. Front Matter
      Pages 1-1
    2. David H. Coy, William A. Murphy, Simon J. Hocart, John Taylor
      Pages 3-16
    3. Terry Reisine, Karen Raynor, Haeyoung Kong, Susan F. Law, Magali Theveniau, Melanie Tallent et al.
      Pages 33-46
    4. I. C. A. F. Robinson
      Pages 47-65
  3. The Immune System and Growth Hormone Interaction

    1. Front Matter
      Pages 85-85
    2. Keith W. Kelley, Sean Arkins, Yong Ming Li
      Pages 87-103
    3. Douglas A. Weigent, J. Edwin Blalock
      Pages 104-115
    4. Nicola Fabris, Eugenio Mocchegiani
      Pages 116-130
  4. Novel Aspects of Growth Hormone Research I

    1. Front Matter
      Pages 131-131
    2. Lester Cohn, Axel G. Feller, Inge W. Rudman, Daniel Rudman
      Pages 133-149
    3. Robert Marcus, Leah Holloway, Gail E. Butterfield
      Pages 150-154
    4. Thierry Abribat, Nathalie Deslauriers, Isabelle Reeves, Dominique R. Garrel, Paul Brazeau
      Pages 155-166
    5. Richard F. Walker, Sei-Won Yang, Ryuji Masuda, Cheng-Shih Hu, Barry B. Bercu
      Pages 167-192
  5. Novel Aspects of Growth Hormone Research II

    1. Front Matter
      Pages 201-201
    2. C. Y. Bowers, K. Veeraragavan, K. Sethumadhavan
      Pages 203-222

About these proceedings


This book is a compendium of proceedings from the Symposium on Growth Hormone II: Basic and Clinical Aspects. The intent of the sym­ posium was to review current aspects of the rapidly expanding science of growth hormone (GH) neuroendocrinology, especially those develop­ ments that occurred since our last meeting in 1985. The meeting was timely since there have been many new and exciting developments in basic research on the GH axis, and several new clinical applications for GH other than growth have been identified. For example, significant strides have been made into use of the bioengineered hormone as an anabolic in debilitated states and as an immunorestorative agent. Both these areas have received most attention as they relate to geriatric popu­ lations. Furthermore, recent focus on a novel family of GH secretagogues that complement the action of GHRH has shown that in animal models, these compounds have the potential to restore GH secretion in deficient or insufficient states, including growth retardation, obesity, and aging. Accordingly, these xenobiotics may have significant potential as drug products to stimulate physiological GH secretion and, thus, resist or reverse some of the maladaptive changes in form and function resulting from GH insufficiency. The importance of these agents as drug candidates is underscored by the diversity of molecules that have been studied by various pharmaceutical companies and the recent discovery that non­ peptide analogs with high oral bioavailability can be synthesized.


Immune System Vivo clinical application glucocorticoids molecular mechanisms neuroendocrinology regulation

Editors and affiliations

  • Barry B. Bercu
    • 1
  • Richard F. Walker
    • 1
  1. 1.Pediatric EndocrinologyAll Children’s HospitalSt. PetersburgUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag New York 1994
  • Publisher Name Springer, New York, NY
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-8374-1
  • Online ISBN 978-1-4613-8372-7